Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder.

ABSTRACT:

Importance

Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population.

Objective

To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder.

Design

This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine.

Setting

A multi-center study including psychiatric healthcare settings in the United States and Europe.

Participants

205 adults with

SUBMITTER: Nemani K 

PROVIDER: S-EPMC11252076 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature